
This study assesses whether antithrombotic prophylaxis with rivaroxaban reduces the risk of venous or arterial thrombotic events, invasive ventilatory support, and death in COVID-19 outpatients. Primary thrombotic and bleeding outcomes, hospitalizations, and deaths will be centrally adjudicated by an independent clinical events committee blinded to the assigned treatment groups. This CARE study provides relevant and contemporary information about the potential role of thromboprophylaxis in outpatients with COVID-19.
Like
Save
Share